We have previously shown that ex-vivo BCR engagement leads to a decrease of membrane CXCR4 expression in CLL cells from patients with unfavourable prognostic factors and at risk of disease progression [10]. This evidence concerns the gene BCR and B-cell chronic lymphocytic leukemia.